Stock Report

All about this stock under one free report Last Updated: 30-Aug-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Alembic Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: APLLTD | BSE: 533573

₹813.45

up-down-arrow ₹-10.55 (-1.28%)

As on 28-Aug-2026IST

Market cap

info icon

₹16,000 Cr

Revenue (TTM)

info icon

₹7,784 Cr

P/E Ratio

info icon

23.1

P/B Ratio

info icon

2.7

Div. Yield

info icon

1.5 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 16.35 25.66 14.12 9.82 7.68
EBIT 68.05 12.81 7.41 10.18 -6.67
Net Profit -29.48 12.11 30.14 13.39 -5.84
EPS -14.62 12.11 14.98 9.48 -7.81
Book Value -- -- 9.32 9.10 2.29
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-26Mar-25
EBIT-Margin info 10.7810.2110.6210.8810.86
Net Margin info 9.198.678.779.078.66
Return on equity info 12.4610.9214.0212.3511.63
Return on Capital info 12.8911.47--11.7413.51
Return on Assets info 8.827.798.338.238.28
Debt to Equity (x) info ----0.020.240.23

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
11.74
13.51
13.42
7.44
Peer Median
--
15.74
14.72
18.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

14.02

Higher than Peers by 3.16

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
14.02
12.35
11.63
13.40
7.12
Peer Median
10.86
13.75
11.67
14.92
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

8.33

Higher than Peers by 1.59

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
8.33
8.23
8.28
9.93
5.15
Peer Median
6.74
8.17
7.86
9.06
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

10.62

Lower than Peers by 2.07

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
10.62
10.88
10.86
10.60
7.65
Peer Median
12.69
14.78
15.03
14.71
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

8.77

Lower than Peers by 0.09

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
8.77
9.07
8.66
9.84
6.05
Peer Median
8.86
8.54
9.33
8.49
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
6.94
6.42
6.61
10.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

14.12

Higher than Peers by 5.98

Year on year growth in net sales

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
14.12
10.08
7.12
10.19
6.54
Peer Median
8.14
14.12
10.27
11.85
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

7.41

Lower than Peers by 9.83

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
7.41
10.37
9.76
52.55
-26.34
Peer Median
17.24
21.59
24.15
28.00
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

30.14

Higher than Peers by 13.28

Year on year growth in profit after tax

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
30.14
15.26
-5.49
80.07
-34.35
Peer Median
16.85
28.31
30.29
36.51
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

14.98

Higher than Peers by 4.38

Year on year growth in earnings per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
14.98
15.66
-5.26
80.07
-34.35
Peer Median
10.60
14.25
24.50
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
9.32
7.74
10.24
-16.55
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

0.02

Lower than Peers by 0.02

Total debt / Net worth

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
0.02
0.24
0.23
0.09
0.15
Peer Median
0.04
0.20
0.23
0.20
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
0.21
0.23
0.09
0.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.75

Higher than Peers by 0.03

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
1.75
1.73
1.67
2.07
1.78
Peer Median
1.72
1.83
1.79
1.96
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

0.78

Lower than Peers by 0.39

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
0.78
0.79
0.76
0.99
0.88
Peer Median
1.17
1.23
1.47
1.44
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

8.42

Higher than Peers by 0.55

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
8.42
8.41
9.98
12.24
8.07
Peer Median
7.86
8.41
9.42
8.58
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

18.84

Lower than Peers by 6.95

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
18.84
19.96
20.98
16.45
18.51
Peer Median
25.79
25.29
25.82
26.12
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.94

Higher than Peers by 0.28

Sales / Average Total Assets

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
0.94
1.75
1.91
2.17
0.85
Peer Median
0.67
0.73
0.75
0.77
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
36.70
32.99
28.10
59.84
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
61.45
53.50
42.32
99.60
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
157.72
164.40
150.62
148.04
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
--
-59.57
-77.92
-80.19
11.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

23.07

Lower than Peers by 16.83

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
23.07
19.28
31.31
31.35
28.50
Peer Median
39.90
39.90
39.70
33.48
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

2.74

Lower than Peers by 1.50

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
2.74
2.29
3.52
4.01
2.23
Peer Median
4.23
4.26
3.72
4.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

1.47

Higher than Peers by 1.37

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
1.47
1.81
1.18
1.12
1.61
Peer Median
0.10
0.10
0.16
0.21
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

13.93

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
13.93
12.08
18.43
20.39
14.49
Peer Median
--
28.71
30.23
29.90
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

16,000

Higher than Peers by 8,388

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-26
Mar-25
Mar-24
Mar-23
Alembic Pharma
16,000
13,009
18,264
19,308
9,748
Peer Median
7,613
6,036
4,851
2,099
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...